Fortrea Tandatangani Perjanjian Definitif untuk Melupuskan Perniagaan Endpoint Clinical dan Patient Access kepada Rakan Kongsi Arsenal Capital

March 12, 2024 by Gias ul Hassan

Cadangan pelupusan perniagaan Endpoint Clinical dan Fortrea Patient Access menyelaraskan lagi fokus strategik Fortrea sebagai organisasi penyelidikan kontrak murni Mencipta penyelesaian Rawak dan Percubaan Pengurusan Bekalan dan Pengurusan Bekalan Percubaan serta Akses Pesakit yang lengkap yang diposisikan untuk pembezaan dan pertumbuhan DURHAM, N.C., March 13, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (“Syarikat”), adalah sebuah organisasi … Read more

Fortrea Menandatangani Perjanjian Definitif untuk Mendivestasi Bisnis Endpoint Clinical dan Patient Access ke Arsenal Capital Partners

March 12, 2024 by Gias ul Hassan

Rencana divestasi bisnis Endpoint Clinical dan Fortrea Patient Access makin merampingkan fokus strategis Fortrea sebagai sebagai organisasi riset kontrak murni. Menciptakan solusi Randomisasi dan Manajemen Pasokan Uji Coba serta Akses Pasien terbaik yang berdiri sendiri, yang disiapkan untuk diferensiasi dan pertumbuhan DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (Perusahaan), sebuah organisasi riset … Read more

Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

February 19, 2024 by Gias ul Hassan

New York, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) — Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The gene therapies in ophthalmology pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. … Read more

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

February 16, 2024 by Gias ul Hassan

SAN FRANCISCO, Feb. 16, 2024 (GLOBE NEWSWIRE) — Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 – Nov. 29, 2023Lead Plaintiff Deadline: Mar. 19, 2024Visit: www.hbsslaw.com/investor-fraud/BIVI Contact An Attorney Now: BIVI@hbsslaw.com … Read more

Lundquist Institute Investigator Dr. Loren Miller to Receive 2024 Top Ten Clinical Research Achievement Award from the Clinical Research Forum

February 15, 2024 by Gias ul Hassan

Los Angeles, California, Feb. 14, 2024 (GLOBE NEWSWIRE) — The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is pleased to announce that Lundquist Investigator Loren Miller, MD, MPH will be honored with a 2024 Top Ten Clinical Research Achievement Awardby the Clinical Research Forum (CR Forum) at a ceremony in Las Vegas, … Read more

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

February 14, 2024 by Gias ul Hassan

Regional Medical Oncology Center is activated and open to screen patients Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously anticipated Q3/24 is now expected by Q1/24 Early data may suggest superiority in safety compared to oral Revlimid® Clinical data reflect the unexpected superior responses seen … Read more

Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep

February 5, 2024 by Gias ul Hassan

Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine. A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive® ergothioneine supports aspects of cognitive function, memory, and sleep in healthy … Read more

The ethics of sharing clinical case photos in dentistry on social media platforms: From an Asian patient context — Lim Ghee Seong, Hayati Ishak and Arilatha Arimuthu

January 22, 2024 by Gias ul Hassan

JANUARY 22 — For the past 10 years or so, the professional communication landscape in the healthcare sector has undergone significant changes due to the widespread use of social media. Among dental clinicians in Asia, a notable trend involves the sharing of clinical photos and case studies on platforms like Facebook and Instagram. Leveraging social … Read more

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

January 10, 2024 by Gias ul Hassan

$Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients$

HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002 evaluating the … Read more

Karolinska Development’s portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

January 9, 2024 by Gias ul Hassan

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst. … Read more

May 21, 2024